Product, Geographic and Other Revenue Information (Tables)

3 Months Ended

Apr. 04, 2021

Schedule of Revenues by Geographic Region


The following summarizes revenues by geographic area:
	Three Months Ended
(MILLIONS)	April 4, 2021		March 29, 2020		% Change
United States	$	7,597	$	5,289	44
Developed Europe	3,038		1,708		78
Developed Rest of World	1,123		919		22
Emerging Markets	2,824		2,166		30
Revenues	$	14,582	$	10,083	45

Schedule of Significant Product Revenues

The following provides detailed revenue information for several of our major products:


(MILLIONS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	April 4, 2021		March 29, 2020
TOTAL REVENUES(a)		$	14,582	$	10,083
Vaccines		$	4,894	$	1,611
BNT162b2 alliance revenues and direct sales	Active immunization to prevent COVID-19	3,462		—
Prevnar 13/Prevenar 13	Pneumococcal disease	1,284		1,450
FSME/IMMUN-TicoVac	Tick-borne encephalitis disease	53		48
Nimenrix	Meningococcal disease	46		75
All other Vaccines	Various	49		38
Oncology		$	2,862	$	2,435
Ibrance	HR-positive/HER2-negative metastatic breast cancer	1,254		1,248
Xtandi alliance revenues	mCRPC, nmCRPC, mCSPC	267		209
Inlyta	Advanced RCC	229		169
Sutent	Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor	200		205
Xalkori	ALK-positive and ROS1-positive advanced NSCLC	134		149
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	123		100
Retacrit(b)	Anemia	109		89
Ruxience(b)	Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis	98		7
Zirabev(b)	Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer	86		6
Lorbrena	ALK-positive metastatic NSCLC	60		42
Aromasin	Post-menopausal early and advanced breast cancer	52		34
Besponsa	Relapsed or refractory B-cell acute lymphoblastic leukemia	50		44
Braftovi	In combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy	47		37
Mektovi	In combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation	35		37
All other Oncology	Various	119		59
Internal Medicine		$	2,594	$	2,332
Eliquis alliance revenues and direct sales	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	1,643		1,300
Chantix/Champix	An aid to smoking cessation treatment in adults 18 years of age or older	217		270
Premarin family	Symptoms of menopause	143		152
Pristiq	Depression	60		41
Toviaz	Overactive bladder	57		60
All other Internal Medicine	Various	474		509
Hospital(a)		$	2,343	$	2,088
Sulperazon	Bacterial infections	192		187
Medrol	Anti-inflammatory glucocorticoid	99		129
Zavicefta	Bacterial infections	94		49
Zithromax	Bacterial infections	89		138
Vfend	Fungal infections	80		74
Fragmin	Treatment/prevention of venous thromboembolism	71		59
EpiPen	Epinephrine injection used in treatment of life-threatening allergic reactions	66		84
Zyvox	Bacterial infections	55		70
Precedex	Sedation agent in surgery or intensive care	55		42
IVIg Products(c)	Various	105		98
Pfizer CentreOne(d)	Various	391		152
All other Anti-infectives	Various	397		395
All other Hospital	Various	648		610
Inflammation & Immunology (I&I)		$	1,065	$	978
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis	538		451
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	319		347


(MILLIONS)		Three Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	April 4, 2021		March 29, 2020
Inflectra/Remsima(b)	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	177		158
All other I&I	Various	31		22
Rare Disease		$	824	$	639
Vyndaqel/Vyndamax	ATTR-cardiomyopathy and polyneuropathy	453		231
BeneFIX	Hemophilia B	112		121
Refacto AF/Xyntha	Hemophilia A	89		89
Genotropin	Replacement of human growth hormone	80		103
Somavert	Acromegaly	65		64
All other Rare Disease	Various	26		31
Total Alliance revenues		$	1,770	$	1,382
Total Biosimilars(b)		$	530	$	288
Total Sterile Injectable Pharmaceuticals(e)		$	1,482	$	1,401

(a)On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See Note 1A. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.

(b)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.

(c)Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.

(d)Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.

(e)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.